Source: ERS Lung Science Conference 2017
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Felix Hermann (Munich, Germany). Cell therapy for lung disease. ERS Lung Science Conference 2017

Member's Comments

No comment yet.

Related content which might interest you: Cell therapy for acute and chronic lung disease Source: International Congress 2014 – Rebuilding: new perspectives on lung bioengineering Year: 2014 Cell therapy in ILD Source: ERS Course 2016 Year: 2016 Cell therapy: a novel approach for the treatment of lung cancer and fibrosis Source: Annual Congress 2010 - Too close for comfort: common pathogenic mechanisms in lung cancer and fibrosis Year: 2010 Severe fibrotic lung disease – How much therapy is too much therapy? Source: Annual Congress 2008 - Clinical Grand Round - an interactive session Year: 2008 Efficacy of functionalized-imatinib loaded gold nanoparticles on lung fibroblastoid cells from systemic sclerosis patients Source: International Congress 2016 – Connective tissue disorders Year: 2016 A possible therapeutic agent for pulmonary fibrosis: Antibody against integrin alpha8beta1 Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation Year: 2013 Stem cell therapy in IPF Source: International Congress 2014 – Targeting lung fibrosis: from bench to bedside Year: 2014 Effect of pirfenidone on IPF progression Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Cultivating bronchial epithelial cells collected through bronchoscopic microsampling in patients with interstitial lung disease Source: International Congress 2016 – ILD pathogenesis Year: 2016 Surfactant protein-D level as a predictor of prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer Source: International Congress 2016 – Orphan diseases I Year: 2016 Fibroblast heterogeneity in the diseased lung Source: International Congress 2014 – ILDs 3 Year: 2014 Coexistence of chronic obstructive pulmonary disease in patients with advanced non-small cell lung cancer and impact on survival Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 The effect of surgical specimen-derived phosphorus and lead concentrations in non-small cell lung cancer patients on disease course Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Lung disease induced by newer therapies for lung cancer: an update Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006 Second-line treatment patients at relapse of disseminated small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 395s Year: 2001 Is sildenafil an effective bridging therapy to lung transplantation for patients with pulmonary hypertension in the setting of lung disease? Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 Crosstalk between lung fibroblasts and T-lymphocytes: Implications for anti-viral responses in chronic lung disease Source: Annual Congress 2013 –Asthma: new mechanisms and markers Year: 2013 Two-stage treatment of non-small cell lung cancer (NSCLC) in patients with severe coronary heart disease. Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019